News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Bard1 Life Sciences.
RELATED STOCKHEAD STORIES
News
Rise and Shine: What you need to know before the ASX opens
News
ASX Small Cap Lunch Wrap: Who’s finding beer in unexpected places today?
News
10 at 10: These ASX stocks have their shareholders feeling festive this morning
Health & Biotech
ASX Health Stocks: M&A winds blow as API gets an upgraded offer from Wesfarmers, jumps 15pc
Health & Biotech
ASX Health Stocks: Osprey jumps 8% on solid first half; Bard1 concludes successful study
Health & Biotech
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
Health & Biotech
ScoPo’s Powerplays: Solid earnings for health stocks all round, but price action stays with larger caps
News
ASX Small Cap Lunch Wrap: Who’s going home with the blues today?
Health & Biotech
Shares in ASX biotechs Nyrada and BARD1 both pop on positive news updates
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Experts
ScoPo’s Powerplays: Hearing tech, medical devices to ride out choppy market
News
ASX Small Cap Lunch Wrap: Who’s about to confess their sins?
Health & Biotech
BARD1 shows off latest technology, potentially disrupting exosome research industry
News
Last Orders: Resources and energy keep ASX in green territory
Health & Biotech
Imugene led a biotech buying frenzy on the ASX today
Health & Biotech
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact
Health & Biotech